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than those for carotid endarterectomy.5-7 Moreover,
angioplasty and stenting of carotid bifurcation lesions in
an ex vivo system has been shown to generate large
amounts of intraluminal particulate debris.8 Nevertheless,
with better selection of patients and improved technology,
lower periprocedural stroke rates were observed with
CBAS.9,10 As a result, some workers have proclaimed that
CBAS is currently equivalent to or superior to carotid
endarterectomy (CEA) and that CBAS should be widely
practiced and used to treat patients with carotid stenoses.
This has led to much controversy and equally strong rec-
ommendations by others that CBAS not be used widely
and that recommendations to do so are inappropriate and
unethical at this time.7,11,12 In most of the conflicting
reports on this topic, there is far more opinion than data.
The result is that the medical profession at large is left con-
fused by the conflicting claims and recommendations of
the overenthusiastic supporters or rabid detractors of
CBAS. Accordingly, they have difficulty in determining
what treatment is best for their patients, and they cannot
provide them with rational recommendations.
To resolve some of the controversy and conflicting
Carotid bifurcation angioplasty and stenting (CBAS)
represents a relatively new and controversial treatment for
patients with atherosclerotic lesions at the junction of the
common and internal carotid arteries. Balloon angioplasty
has been used sporadically for many years to treat patients
with carotid bifurcation stenoses.1,2 However, it was only
after intravascular stents became available that any enthu-
siasm was generated for the endovascular management of
these lesions.3-6 Despite the fact that angiographically
favorable results were often achieved, the procedural
stroke rates in many of the earlier series remained higher
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Objective: Carotid bifurcation angioplasty and stenting (CBAS) has generated controversy and widely divergent opinions
about its current therapeutic role. To resolve differences and establish a unified view of CBAS’ present role, a consensus con-
ference of 17 experts, world opinion leaders from five countries, was held on November 21, 1999.
Methods: These 17 participants had previously answered 18 key questions on current CBAS issues. At the conference these
18 questions and participants’ answers were discussed and in some cases modified to determine points of agreement (con-
sensus), near consensus, (prevailing opinion), or divided opinion (disagreement).
Results: Conference discussion added two modified questions, placing a total of 20 key questions before the participants,
representing four specialties (interventional radiology, seven; vascular surgery, six; interventional cardiology, three; neuro-
surgery, one). It is interesting that consensus was reached on the answers to 11 (55%) of 20 of the questions, and near con-
sensus was reached on answers to 6 (30%) of 20 of the questions. Only with the answers to three (15%) of the questions
was there persisting controversy. Moreover, both these differences and areas of agreement crossed specialty lines.
Consensus Conclusions: CBAS should not currently undergo widespread practice, which should await results of randomized
trials. CBAS is currently appropriate treatment for patients at high risk in experienced centers. CBAS is not generally appro-
priate for patients at low risk. Neurorescue skills should be available if CBAS is performed. When cerebral protection devices
are available, they should be used for CBAS. Adequate stents and technology for performing CBAS currently exist. There
were divergent opinions regarding the proportions of patients presently acceptable for CBAS treatment (<5% to 100%, mean
44%) and best treated by CBAS (<3% to 100%, mean 34%). These and other consensus conclusions will help physicians in
all specialties deal with CBAS in a rational way rather than by being guided by unsubstantiated claims. (J Vasc Surg
2001;33:S111-6.)
recommendations regarding CBAS, it was decided to hold
a conference of opinion leaders on this topic. The purpose
of this consensus conference, which included experts from
several disciplines interested in this new method of treat-
ing patients with carotid lesions, was to reach agreement
or consensus on as many key issues related to this new
treatment modality as possible. This article summarizes
the results of this consensus-seeking process and should
provide a balanced overview of CBAS and its current role
in the treatment of patients with carotid bifurcation
lesions. This information should prove valuable to the
medical community at large in their efforts to apply this
new treatment rationally and appropriately to patients
with carotid bifurcation stenosis caused by arteriosclerosis.
METHODS
To provide the most informed, balanced overview of
the topic, the consensus conference organizers (F.J.V. and
M.A.) selected as participants those individuals who were
generally acknowledged to be the best and brightest leaders
in the field. This meant those physicians who, irrespective of
the specialty they represented, had the widest experience
and greatest interest in CBAS. Seventeen participants were
chosen from four different specialties (Interventional
Radiology, Interventional Cardiology, Vascular Surgery, and
Neurosurgery) and five different countries (United States,
United Kingdom, Canada, Germany, and France). As
shown in Table I, seven of these participants were interven-
tional radiologists, three were interventional cardiologists,
and seven were surgeons (six vascular surgeons and one
neurosurgeon). All 17 participants had a clear endovascular
orientation, and all but three were major endovascular ther-
apists. Thus the conference participants were unlikely to
represent the views of “surgical foxes guarding the carotid
stenosis henhouse,” as one participant had worried about
when the conference was in the planning stage. All confer-
ence participants had performed clinical or laboratory stud-
ies of CBAS and had published and lectured widely on this
topic. All 17 of the selected participants agreed to take part
in the consensus process.
Before the Oral Consensus Conference
All 17 participants were sent a questionnaire requesting
their responses to 15 key questions relating to the present
status of CBAS. These questions were designed to evaluate
current points of agreement or disagreement about the pre-
sent role of CBAS in medical practice. The answers to these
questions plus discussion of these questions and their
answers at the oral consensus session would serve as a major
basis for the written documentation that would result from
the consensus process. The questionnaire had room for
comments in addition to the “yes,” “no,” or “uncertain”
answers that were possible for most of the questions. All 17
participants returned their completed questionnaire in time
for the answers to be collated and analyzed before the oral
session. Thus the answers to the questions could be dis-
cussed effectively at the oral session. In addition, one of the
participants believed that an additional three questions
should be asked, answered, and discussed at the oral session
so that a better, more complete overview of CBAS might be
obtained. These three questions were also circulated and
answered by all 17 participants. Analysis of these three addi-
tional questions were also completed so that they could be
discussed at the oral session.
Oral Consensus Conference
This conference was held in New York City on
November 21, 1999. Twelve participants in addition to
Drs. Veith and Amor attended. Five participants were
unable to attend because of previous commitments or
urgent conflicts. One absent participant’s views were rep-
resented at the oral session by his colleague who was in
attendance (Amman Bolia for Peter Bell). Questions and
comments from an audience of 250 interested physicians
were also entertained by the oral session participants.
The oral session consisted of a 10-minute introduc-
tory statement outlining the purpose and structure of the
oral session and the documentation that would result. A
summary and analysis of the answers to each of the 18
questions asked in the questionnaires was then presented.
Discussion of each question and its answers then followed.
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Table I. Listing of the 17 consensus participants, their specialty affiliation, and their home country
Radiologists Cardiologists Surgeons
Bolia* USA Henry* France Beebe USA
Connors* USA Roubin* USA (Bell)‡ UK
Ferguson* Canada Yadav* USA Bergeron* France
(Katzen)* USA Diethrich* USA
(Matthias)* Germany Hobson USA
(Theron)* France Hopkins*† USA
(Wholey)* USA Ohki* USA
Names in parentheses indicate those who contributed to the questionnaire but were unable to attend the oral session.
*Major endovascular therapist.
†Neurosurgeon.
‡Represented at oral conference by Dr. Bolia.
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In some cases questions were modified to permit answers
on which most participants could agree. In other instances
participants’ answers were changed as the question was
clarified by the discussion. An effort was made by all to
reach consensus or near consensus on as many aspects of
CBAS as was currently possible.
After these discussions of each question, each of the
12 participants in attendance presented a 5- to 10-minute
oral summary of the key points he wished to make on the
topic. Each presentation was discussed by the other par-
ticipants present. Again, a major goal of all present was to
resolve areas of disagreement, if possible.
Written Documentation of the Consensus
Process
This article summarizes the participants’ responses to
the 18 questions originally posed and the two modifica-
tions to these questions and their answers that were arrived
at during the discussion at the oral consensus conference.
Based on these answers and the accompanying discussion,
this article will also provide a broad overview-summary of
the current, generally agreed-on role of CBAS in the treat-
ment of patients with carotid bifurcation stenosis. And
finally, it will provide a summary-discussion of the authors’
views and predictions of the future role of CBAS in the
treatment of patients with carotid disease and what ques-
tions must be answered for that role to be determined.
In addition to this article, a book will be published rep-
resenting the results of the consensus process in greater
detail. Also included in this book will be a series of articles
from 14 of the 17 consensus participants. As part of the
consensus process, all these participants were asked to write
these articles, which would summarize their personal expe-
rience with CBAS and their current opinions and future
predictions about its place in the treatment of patients.
DEFINITIONS
Answers to all questions were collated and analyzed
according to the following definitions (Table II). If 12 or
more of the 17 responding participants agreed on a response
to a question about CBAS, that answer was considered to
represent consensus or general agreement. If 10 or 11 of the
17 respondents agreed on a response, that response was con-
sidered to represent near consensus or prevailing opinion.
Near consensus was also reached when nine respondents
agreed on a response while two or three were uncertain and
five or six disagreed. If only nine or fewer of the 17 partici-
pants agreed on a response to a question, that response was
considered an area of divided opinion, disagreement, or
uncertainty.
RESULTS
A. Overall Results Of the 18 questions originally
posed to the conference participants, consensus or agree-
ment with regard to the answer was attained on nine and
near consensus or prevailing opinion on six. The answers to
the three remaining original questions reflected divided
opinion or wide ranges of opinion based on conflicting
views, uncertainty, or actual disagreement. In addition, at the
oral session two derivative or altered questions were posed.
With these minor alterations in the question, the answers
were converted from “prevailing opinion” to consensus.
Thus consensus was reached on 11 of 20 or 55% of the
answers to key questions posed, and near consensus was
reached on 6 of 20 or 30% of the answers. Only in the
answers to 3 of the 20 or 15% of the questions was there a
wide range of divergent opinions. These overall results reflect
a remarkable degree of agreement among the experts on this
controversial topic.
B. Consensus or Agreement Reached The confer-
ence participants reached consensus or agreement on
answers to the following 11 questions relating to crucial
issues concerning CBAS.
1. Should CBAS undergo widespread practice
(ie, be standard of care) currently? Of the 17
respondents, 14 answered no. Two others who voted yes
would advocate use of CBAS only for specific indications
or surgically unfit patients. Otherwise, these two partici-
pants, one a radiologist and one a surgeon, would have
voted no. Thus clear consensus was reached that CBAS
should not currently be recommended for widespread
practice, that is, become the standard of care.
2. Should widespread (ie, standard of care)
CBAS await results of randomized studies? Of the
17 participants, 12 answered yes. One respondent, a radiol-
ogist, would vote yes if the question was not applied to
patients at high risk for whom he deemed registries to be
adequate. Thus consensus was reached that widespread
application of CBAS should await the results of randomized
prospective trials.
3. Is CBAS currently appropriate only for
low risk (NASCET eligible) patients? Of the 17
participants, 16 answered no. Thus clear consensus was
reached that CBAS should not currently be considered
appropriate only for patients at low risk. Parenthetically,
one respondent commented that the CREST Trial should
Table II. Definitions of the criteria for determin-
ing the results of the consensus process
•17 Respondents
•≥12/17 = Consensus (agreement)
•10-11/17 = Prevailing opinion (near consensus)
(or 9/17 + 2-3 uncertains)
•< 9/17 = Divided opinion/disagreement/uncertainty
All of the original 18 questions had answers from all 17 partici-
pants. The two derivative questions had responses from the 13
participants represented at the oral consensus conference.
be performed only after high-risk registry results were
available.
4. Must high-level neurointerventional skills
and techniques be available to perform CBAS? Of
the 17 participants, 12 answered yes, 3 (2 cardiologists and
1 surgeon) answered no, and 2 (surgeons) were uncertain.
One surgeon commented that the skills and techniques
need not be possessed by the CBAS operator but should be
available within the same institution. Thus consensus was
reached that high-level neurorescue skills and techniques
must currently be available to perform CBAS.
5. Is the optimal stent for use in CBAS cur-
rently defined? Of the 17 participants, 13 answered no,
1 surgeon answered yes, and 3 (2 radiologists and 1 sur-
geon) indicated their uncertainty. Thus consensus was
reached that the optimal stent for use in CBAS was not
currently defined.
Despite this, one cardiologist commented that current
stents were adequate, and one surgeon commented that
nitinol stents will probably replace stainless steel stents.
6. Assuming comparable immediate and late
results between CBAS and carotid endarterec-
tomy (CEA), should CBAS be offered to patients
in some circumstances? Of the 17 participants, 14
answered yes. Three respondents (one radiologist and two
surgeons) answered no. However, four respondents who
acknowledged that there were currently no data to justify
the assumption implied in this question. Nevertheless,
consensus was reached that if the assumption of equivalent
results for CBAS and CEA could be shown, then CBAS
should be offered to patients in some circumstances.
7. Would you offer CBAS to patients in all
possible circumstances in which treatment of
carotid stenosis was indicated? Of the 17 partici-
pants, 13 answered no. Thus consensus was reached that
CBAS should not be offered to patients requiring treat-
ment of carotid bifurcation stenosis in all circumstances.
Three respondents commented that this could only be
done when validated data were available to justify such
practice.
8. In what circumstance is CBAS presently
justified in experienced centers? Consensus was
reached on five presently justifiable indications for CBAS
in patients requiring treatment for carotid bifurcation
stenoses. These were (1) high-risk* patients with symp-
toms, (2) recurrent stenosis, (3) previous radical neck dis-
section or cervical irradiation, (4) high* bifurcation or extent
of the carotid lesion, and (5) indications for CEA, but
patient unfit* for surgery. (* Term not specifically defined.)
In addition, the prevailing opinion (8 of 12 of those
present at the oral session) was that CBAS was also justi-
fied in patients with indications for CEA in the presence of
a contralateral internal carotid occlusion. A minority (4 of
12) of the participants, whose experience showed mini-
mally increased risk of CEA in this circumstance, believed
that this was not an indication for CBAS.
9. What conditions currently contraindicate
CBAS? Consensus was reached on five current con-
traindications. These were (1) intraluminal thrombus, (2)
complex* bifurcation lesions, that is, long multifocal
lesion or an angulated internal carotid artery, (3) exten-
sive* aortic or brachiocephalic trunk plaque; severe* tor-
tuosity or calcification of the aortic arch vessels, (4)
ringlike heavy calcification of the carotid bifurcation, (5)
neurologically unstable patient or a stroke within 3 weeks
of the intended CBAS (* term not specifically defined).
Young patients (<65 or <55 years of age) were also
considered by some participants to be poor candidates for
CBAS, but this contraindication was believed to be inap-
propriate by most who attended the oral session.
Consensus was also reached by participants at the oral
session on two modified original questions that had been
posed. Answers to the original questions were consistent
with near consensus or prevailing opinion. However, a
number of participants altered their answers with the
modified questions to produce consensus. The modified
questions and their consensus answers were as follows.
10. When cerebral protection devices become
available, CBAS should only be performed with
some form of such device? All 12 of the oral session par-
ticipants agreed (clear consensus) that when cerebral protec-
tion devices were available, they should be used for CBAS.
However, three participants acknowledged that the value of
these devices in lowering the incidence of periprocedural
stroke has not been proven conclusively. The remaining par-
ticipants believed that current evidence was adequate to
mandate use of these devices when they are available.
11. Are adequate stents and technology for
performing CBAS currently available, if cerebral
protection devices were available and effective?
Of the 17 participants, 12 answered this question yes, 4
answered no, and 3 were uncertain. Thus consensus was
reached that adequate stents and technology are currently
available for the performance of CBAS, when effective
cerebral protection devices are included.
C. Near Consensus or Prevailing Opinion
Reached The conference participants reached near con-
sensus or prevailing opinion on answers to the following
questions.
1. Are the optimal techniques for performing
CBAS currently defined? Of the 17 participants, 11
answered no and 6 answered yes. Thus the prevailing
opinion was that optimal techniques for performing CBAS
are not currently defined. One cardiologist commented
that this was a technique in evolution. One radiologist
indicated the need for more dedicated designs of stents
and introducer devices for CBAS.
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2. Is CBAS currently appropriate for high-
risk patients only? Of the 17 participants, 11
answered yes and 6 answered no. Thus the prevailing
opinion was that CBAS was currently appropriate only for
patients at high risk. Conceivably, some of the respon-
dents who voted no did so because they believed that
CBAS should not be limited only to patients at high risk.
If that were the case, it would only strengthen the pre-
vailing opinion that CBAS was currently appropriate for
patients at high risk.
One surgeon commented that there was, however, a
need to define patients at high risk precisely. The affirma-
tive answers to this question were given by four radiolo-
gists, one cardiologist, and six surgeons. The negative
answers were given by three radiologists, two cardiolo-
gists, and one surgeon. Thus the prevailing opinion was
expressed across specialty lines.
3. Is CBAS currently appropriate for high-
and low-risk patients? Of the 17 participants, 10
answered this question no, 5 answered yes, and 2 were
uncertain. Thus the prevailing opinion was that CBAS is
not currently appropriate for patients at high and low risk.
Of the 10 negative answers, 3 were given by radiolo-
gists, 1 by a cardiologist, and 6 by surgeons. Thus again
the prevailing opinion was expressed across specialty lines.
The two uncertain answers were expressed by radiologists
who believed that clinical trials were needed to define indi-
cations precisely.
4. For CBAS operators with complication
rates equal to or better than guidelines for CEA,
should they presently be able to offer their
patients a carotid stenting option? Of the 17 par-
ticipants, 11 answered this question yes and 6 answered no.
Three of the individuals who answered negatively com-
mented that there was insufficient valid comparative data in
comparable patients to justify an affirmative answer. This
lack of data was particularly evident with regard to late
results. Nevertheless, the prevailing opinion was that CBAS
operators with complication rates equivalent to those for
CEA should presently be able to offer some patients a
stenting option. Again, this prevailing opinion was
expressed by individuals from all three specialties (five radi-
ologists, three cardiologists, and three surgeons).
5. Should CBAS currently only be performed
with some form of cerebral protection device? Of
the 17 participants, 9 answered this question no, 5
answered yes, and 3 were uncertain. Thus the prevailing
opinion was that CBAS currently can be performed with-
out a cerebral protection device. It should be noted, how-
ever, that the European respondents largely answered yes
to this question, probably because such devices are avail-
able to them. On the other hand, U.S. respondents tended
to answer no because such devices are not presently avail-
able in the United States. It is also noteworthy that three
participants (one radiologist, two surgeons) considered
the value of cerebral protection devices unproven.
When the question was modified slightly (at the oral
session [see consensus question 10]), clear consensus was
reached that CBAS should only be performed with some
form of cerebral protection device when such devices were
available.
6. Are adequate stents and technology for
performing CBAS currently available? Of the 17
participants, 10 answered yes, 4 answered no, and 3 were
uncertain. Thus the prevailing opinion was that adequate
stents and technology for performing CBAS are currently
available. That opinion was expressed across specialty lines
(four radiologists, two cardiologists, and four surgeons).
When the question was slightly modified at the oral ses-
sion to assume that effective cerebral protection devices
were available, a consensus affirmative answer to this ques-
tion was obtained (see consensus question 11).
D. Divided Opinion or Disagreement
1. Should a Food and Drug Administration
Investigational Device Exemption (IDE) be
required to perform CBAS in the USA - or com-
parable approval elsewhere? Of the 17 participants, 9
answered no and 8 answered yes. Thus opinion on this
question was clearly divided. One surgeon commented that
an IDE should be required except for an occasional case.
One radiologist commented that IDEs should only be
required during clinical trials. The eight affirmative answers
were from three radiologists, one cardiologist, and four
surgeons; the nine negative answers were from four radiol-
ogists, two cardiologists, and three surgeons. Thus there
was no specialty bias for either answer. It is noteworthy that
the Food and Drug Administration has indicated that per-
formance of CBAS without an IDE is “in contravention of
Food and Drug Administration regulations.13
2. What proportion of patients requiring
treatment for carotid bifurcation disease are
presently acceptable for CBAS? The 17 participants
had a wide range of proposed percentages in answer to this
question. These divergent opinions ranged from less than 5%
to approximately 100%, with a mean of 44%. There was also
a wide range of overlapping answers within each specialty,
although the highest responses (>60%) were in the answers
of the interventional specialists. Radiologists’ answers were
less than 5%, 6%, 15%, 80%, 90%, approximately 100%, and
uncertain (mean 49%). Cardiologists’ answers were 40%,
80%, and 95% (mean 72%). Surgeons answers were 5%, 10%,
20%, 20%, 35%, 60%, and uncertain (mean 25%).
3. What proportion of patients requiring
treatment for carotid bifurcation disease are
presently best or optimally treated by CBAS?
Again, the 17 participants had a wide range of proposed
percentages in answer to this question. These divergent
opinions ranged from less than 3% to approximately 100%,
with a mean of 34%. Again, there was a wide range of over-
lapping answers within each specialty. Radiologists’ answers
were 3%, less than 5%, 15%, 45%, 90%, approximately 100%,
and uncertain (mean 43%). Cardiologists’ answers were
25%, 80%, and uncertain (mean 53%). Surgeons’ answers
were less than 3%, less than 5%, 5%, 15%, 20%, 25%, and
50% (mean 18%).
DISCUSSION
The consensus process brought together 17 of the
world’ s leading experts on CBAS. These 17 were asked
key questions regarding the procedure and its present role
in treating patients with carotid bifurcation arteriosclero-
sis. All 17 expressed themselves willingly and freely.
All who participated in this consensus endeavor on
CBAS believed that the effort was worthwhile. Although
widely divergent opinions exist between individuals and
specialties with regard to this topic, all who took part in
the consensus process were surprised by the degree of con-
sensus and near consensus that existed when the experts in
the field answered specific key questions and discussed
both the questions and individual answers and interpreta-
tions of these answers. Even though there were a few dif-
ferences of opinion and areas of disagreement and
uncertainty, these were far outweighed by the points of
clear agreement (consensus) and prevailing opinions (near
consensus). It was also surprising to note that differences
of opinion within the three specialties that were repre-
sented in the consensus process were far greater than dif-
ferences of opinion between these three specialties. The
one exception to this was a tendency toward the more lib-
eral application of CBAS by the interventional specialists
than by the surgical specialists, although again, there was
considerable overlap between the specialties.
Even though these conference participants included
enthusiastic supporters of wider adoption of CBAS, con-
sensus was reached that clinical use of the procedure
should currently be restricted to patients at high risk. It
was further agreed that widespread practice of CBAS in
patients at low risk should await the results of randomized
prospective clinical trials comparing CBAS with CEA. It
was also agreed that CBAS would almost certainly have a
role in clinical practice, but precise definition of that role
awaits further clarification. It was also agreed that CEA
would have an important role in the treatment of patients
with carotid bifurcation disease, although opinions varied
greatly on what that role may be. The conference partici-
pants also agreed on the importance of cerebral protection
in CBAS. Because embolic particles are universally gener-
ated by the procedure,8 all agreed that some method to
intercept these particles must be used. However, again,
precise definition of which type of cerebral protection
device (distal balloon, filter, or proximal balloon catheter)
will prove to be best remains to be determined.
Thus the consensus process revealed that we are at the
beginning of an exciting new treatment, CBAS. Much
remains to be learned about this treatment, how it should
best be performed, what stent or stents will be best, and
where it will fit into the treatment of patients with carotid
disease. However, it is clear that CBAS is currently justified
for certain specific indications, that it should be evaluated
in other circumstances by appropriate prospective trials,
and that it will continue to generate interest and contro-
versy for some time to come. However, for the present, it
is hoped that the agreement reached in the consensus
process will help to guide medical practitioners throughout
the world in the appropriate and cautious application of
this new technology. By using the information derived
from this consensus conference, physicians can apply this
technology more rationally and treat their patients better in
an effort to prevent strokes.
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